Examining the association between vaccine reactogenicity and antibody titer 
dynamics after the third dose of BNT162b2 vaccine using a mixed-effects model

Matsumoto, Naomi; Hagiya, Hideharu; Nakayama, Masanori; Furukawa, Masanori; Mitsuhashi, Toshiharu; Takao, Soshi; Otsuka, Fumio; Yorifuji, Takashi

doi:10.1016/j.jiac.2022.09.012

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Examining the association between vaccine reactogenicity and antibody titer dynamics after the third dose of BNT162b2 vaccine using a mixed-effects model

MPS-Authors

/persons/resource/persons224376

Nakayama, Masanori
Cell Polarity and Organogenesis, Max Planck Institute for Heart and Lung Research, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Matsumoto, N., Hagiya, H., Nakayama, M., Furukawa, M., Mitsuhashi, T., Takao, S., et al. (2023). Examining the association between vaccine reactogenicity and antibody titer dynamics after the third dose of BNT162b2 vaccine using a mixed-effects model. JOURNAL OF INFECTION AND CHEMOTHERAPY, 29(1), 39-42. doi:10.1016/j.jiac.2022.09.012.

Cite as: https://hdl.handle.net/21.11116/0000-000C-34A9-B

Abstract

Background: To mitigate the COVID-19 pandemic, many countries have recommended the use of booster vac-cinations. The relationship between the degree of adverse vaccine reactions and elevated antibody titers is of interest; however, no studies have investigated the temporal changes in antibody titers based on repeated measurements after a third dose of the BNT162b2 vaccine. Methods: This prospective longitudinal cohort study was conducted with 62 healthcare workers who received a third dose of the BNT162b2 at Okayama University Hospital, Japan. Venous blood draw and fingertip whole blood test sample collection were conducted at the early (3-13 days) and 1-month time points; only FWT sample collection was conducted at the 2-month time point. Information on adverse reactions within 1 week after vaccination was also obtained. The association between fever of 37.5 degrees C or higher and antibody titers after the third dose of BNT162b2 was examined using a mixed-effects model and Poisson regression with robust variance. Results: A trend toward higher antibody titers in the early period after vaccination was observed in the febrile individuals, but the differences were not significant at 1 and 2 months post-vaccination (the partial regression coefficient for fever was 8094.3 [-1910.2, 18,098.8] at 1 month after vaccination, and 1764.1 [-4133.9, 7662.1] at 2 months after vaccination in the adjusted models). Conclusion: The findings suggest that the presence of fever after the third vaccine does not predict a sustained elevation in serum antibody titers.